With a new fit-for-purpose facility for viral vector manufacturing currently in the design and construction phase, Avid Bioservices’ expansion into cell and gene therapy is poised to fill an observed unmet need in the space by prioritizing a customer-centric approach and emphasizing flexibility while leveraging its legacy quality record.
Considering our history and approach to customer-centricity, Avid is perfectly positioned to add value to clients in this upcoming market:
Learn more about the motivation for Avid Bioservices’ entry into the viral vector space, and the unique and differentiated value the company offers cell and gene therapy innovators.
Please enter your contact information to download the article. Fields marked with a * are required.